The CES2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the CES2 gene in human Raji B lymphocytes. This heterogeneous pool of gene-disrupted cells provides a population-level loss-of-function model, avoiding the clonal selection biases inherent to monoclonal lines. The polyclonal format captures the breadth of editing outcomes, enabling robust studies of CES2 function in a widely used B-cell lymphoma background.
The Raji cell line is an EBV-positive Burkitt lymphoma B-lymphocyte model derived from a patient with African Burkitt lymphoma. It retains characteristic B-cell properties, including constitutive antibody secretion and antigen presentation, and serves as a platform for investigating immune surveillance and viral oncogenesis. Raji cells are extensively used in hematologic cancer research, drug screening, and immunopharmacology due to their suspension growth and well-characterized signaling pathways.
CES2 is a serine esterase that hydrolyzes the carbamate bond of irinotecan to generate SN-38, a potent topoisomerase I (TOP1) inhibitor. SN-38?CTOP1 complexes cause DNA damage, activating damage response proteins and triggering apoptosis. CES2 expression is regulated by nuclear receptors PXR (NR1I2) and CAR (NR1I3), transcription factor HNF4A, and inflammatory cytokine IL-6. This prodrug activation pathway is central to irinotecan’s anticancer efficacy and its dose-limiting toxicities, making CES2 a critical node in tumor cell drug sensitivity.
In Raji B lymphocytes, CES2 knockout ablates irinotecan-to-SN-38 conversion, rendering cells resistant to irinotecan-induced cytotoxicity. This model allows dissection of CES2-dependent prodrug activation within a lymphoid malignancy context, where irinotecan-based therapies may be considered. The system is particularly relevant for studying mechanisms of chemotherapy resistance and for evaluating the impact of altered CES2 expression on irinotecan-associated adverse effects such as severe diarrhea.
Applications include Western blotting and RT-qPCR to confirm CES2 disruption, MTT-based cytotoxicity assays to measure irinotecan resistance, fluorometric esterase activity assays, LC-MS quantification of SN-38 intracellular levels, and flow cytometric apoptosis detection. These tools support ADME-Tox studies, drug metabolism investigations, and cancer pharmacology research. For further information, please contact Ascent Research.
